文献速递心力衰竭与心肌病

机器学习驱动的转甲状腺素蛋白淀粉样心肌病风险预测模型

Machine Learning-Driven Risk Prediction Model in Transthyretin Amyloid Cardiomyopathy.
PubMed 文献 · JAMA Cardiol · 2026-01-01

本研究基于瑞士心脏淀粉样变性登记处和维也纳心脏淀粉样变性登记处的850例确诊ATTR-CM患者,开发并验证了随机生存森林机器学习预后模型。模型在三个队列中的Harrell一致性指数为0.72-0.77,3年AUC为0.73-0.80,判别能力较国家淀粉样变性中心和Mayo诊所分期系统提高2%-10%(C指数)和3%-19%(3年AUC)。

要点

  • 机器学习模型在ATTR-CM患者中预测全因死亡和心衰住院复合终点,判别能力优于现有分期系统。
  • 模型在三个独立队列中验证,Harrell C指数0.72-0.77,3年AUC 0.73-0.80。
  • 模型校准度可接受,在接受疾病修饰治疗亚组中性能仍满意。

核心结论

  • 基于随机生存森林的机器学习时间-事件预测模型在ATTR-CM患者中展现出良好的预测性能,判别能力优于国家淀粉样变性中心和Mayo诊所分期系统,支持其用于个体化预后评估的潜力。

研究设计与样本

  • 采用随机生存森林模型,通过内部-外部交叉验证评估,每次留出一个中心作为验证集,并与国家淀粉样变性中心和Mayo诊所分期系统比较。

主要发现

  • 模型在Bern-Swiss队列(n=352)的Harrell一致性指数为0.74(95%CI 0.69-0.78),3年AUC为0.73(95%CI 0.66-0.80)。
  • 模型在Other-Swiss队列(n=260)的Harrell一致性指数为0.77(95%CI 0.69-0.83),3年AUC为0.80(95%CI 0.70-0.88)。
  • 模型在Vienna队列(n=238)的Harrell一致性指数为0.72(95%CI 0.67-0.77),3年AUC为0.75(95%CI 0.67-0.83)。
  • 与现有分期系统相比,模型Harrell一致性指数提高2%至10%,3年AUC提高3%至19%。
  • 模型校准度在各队列和各时间点总体可接受,在接受疾病修饰治疗的患者亚组中性能仍满意。

临床怎么用

  • 该机器学习模型可用于ATTR-CM患者的个体化预后评估,辅助识别高风险患者。
  • 模型判别能力优于现有分期系统,可考虑在临床决策中整合使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Transthyretin cardiac amyloidosis (ATTR-CM) is associated with poor prognosis and significant morbidity and mortality, yet existing staging systems have limited ability to accurately predict outcomes in contemporary patient populations. OBJECTIVE: To develop and validate a machine learning (ML)-based prognostic model for patients with ATTR-CM. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study, including specialized referral centers for cardiac amyloidosis, used data from patients with confirmed ATTR-CM in the Swiss Cardiac Amyloidosis Registry (February 2018 to November 2025) and the Cardiac Amyloidosis Registry of the Medical University of Vienna (July 2014 to February 2025). A random survival forest model was developed and evaluated through internal-external cross-validation, with each center iteratively held out for validation. The model was compared with the National Amyloidosis Centre and Mayo Clinic staging systems. Data analysis was conducted from December 2025 to February 2026. EXPOSURE: Clinical, demographic, medication, laboratory, and echocardiographic variables were used to train an ML-based time-to-event prediction model. MAIN OUTCOMES AND MEASURES: The primary outcome was defined as a composite event of all-cause mortality and hospitalization for heart failure. RESULTS: A total of 850 patients (median [IQR] age, 79 [74-83] years; 750 [88.2%] male) were included across 3 cohorts (from Bern, Switzerland [Bern-Swiss cohort], n = 352; the other centers from Switzerland combined [Other-Swiss cohort], n = 260; and Vienna, Austria [Vienna cohort], n = 238). The random survival forest model demonstrated good discrimination across all held-out cohorts, with Harrell concordance indices of 0.74 (95% CI, 0.69-0.78), 0.77 (95% CI, 0.69-0.83), and 0.72 (95% CI, 0.67-0.77) for the Bern-Swiss, Other-Swiss, and Vienna cohorts, respectively, and 3-year area under the curve (AUC) of 0.73 (95% CI, 0.66-0.80), 0.80 (95% CI, 0.70-0.88), and 0.75 (95% CI, 0.67-0.83), respectively. The model showed improved discrimination compared with the National Amyloidosis Centre and Mayo Clinic staging systems, with Harrell concordance indices 2% to 10% higher and 3-year AUC improvements ranging from 3% to 19% across cohorts and scoring systems. Calibration was generally acceptable across cohorts and time points. Model performance remained satisfactory in the subgroup of patients receiving disease-modifying therapy. Explainability analyses identified clinically plausible drivers of risk. CONCLUSIONS AND RELEVANCE: An ML-based time-to-event prediction model demonstrated promising predictive performance and showed improved discrimination compared with established staging systems in patients with ATTR-CM, supporting its potential for individualized prognostication.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Baj G, Ciocca N, Mohammadi Kazaj P, et al. Machine Learning-Driven Risk Prediction Model in Transthyretin Amyloid Cardiomyopathy. JAMA Cardiol. 2026. PMID: 42663418. doi:10.1001/jamacardio.2026.3496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。